RecruitingAdvanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Eligible age

All ages

Accepts

All genders

Locations

44 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Sponsor: National Cancer Institute (NCI)

You may qualify if…

✓ Patient must have measurable disease
✓ Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2 OR patient must have Lansky performance status of \>= 50% or Karnofsky performance status of \>= 50%
✓ Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider
✓ All patients must have sequencing results available from a National Cancer Institute (NCI) credentialed Designated Laboratory (DL)
✓ Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy and meet one of the following criteria:
✓ Patients must have progressed on at least one line of standard systemic therapy OR
✓ Patients whose disease has no standard treatment that has been shown to prolong overall survival
✓ Patient must meet one of the following requirements: